Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling

Daniela Montagna, Roberta Schiavo, Nadia Gibelli, Paolo Pedrazzoli, Roberto Tonelli, Sara Pagani, Elisa Assirelli, Franco Locatelli, Andrea Pession, Vittorio Fregoni, Elisa Montini, Gian Antonio Da Prada, Salvatore Siena, Rita Maccario

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Successful ex-vivo priming and long-term maintenance of anti-tumor cytotoxic T-cell (CTL) lines are preliminary conditions for their use in approaches of adoptive immunotherapy for patients with cancer. We describe the results of a novel procedure for generating in vitro anti-tumor CTL using CD8-enriched peripheral blood mononuclear cells (PBMC) and dendritic cells (DC), pulsed with irradiated tumor cells (TC) as source of tumor antigen. Eight patients were enrolled in our study: 4 sarcoma, 2 renal cell carcinoma, 1 ovarian carcinoma and 1 breast carcinoma. Ten anti-tumor CTL-lines cytotoxic towards patient TC were generated. Five CTL-lines were obtained using both DC and PBMC from the patients (autologous setting). For 5 CTL-lines, DC derived from an HLA-identical sibling were employed (allogeneic setting): patients or siblings PBMC were used to generate CTL-lines in 2 and 3 cases, respectively,. After tumor-specific rounds of stimulation, followed by antigen-independent cycle of expansion, CTL-lines obtained in both autologous and allogeneic setting showed an expansion of the absolute number of cultured cells. In 6 of 10 CTL-lines, the majority of effector cells (>70%) were CD3+/CD8+, while in the remaining 4, 40-70% of effector cells were CD3+/CD4+. Both CD8+ and CD4+ T cells displayed anti-tumor cytotoxic activity. Spectratyping analysis of the TCR-Vβ subfamilies revealed a preferential expansion of oligoclonal populations in 18 of 24Vβ subfamily. Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy.

Original languageEnglish
Pages (from-to)76-86
Number of pages11
JournalInternational Journal of Cancer
Volume110
Issue number1
DOIs
Publication statusPublished - May 20 2004

Fingerprint

Siblings
T-Lymphocytes
Cell Line
Neoplasms
Dendritic Cells
Adoptive Immunotherapy
Blood Cells
Neoplasm Antigens
Sarcoma
Cultured Cells
Breast Neoplasms
Carcinoma
Antigens
Population

Keywords

  • Adoptive immunotherapy
  • Dendritic cells
  • Graft- vs.-tumor
  • Solid tumors
  • Tumor-specific T-cell lines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. / Montagna, Daniela; Schiavo, Roberta; Gibelli, Nadia; Pedrazzoli, Paolo; Tonelli, Roberto; Pagani, Sara; Assirelli, Elisa; Locatelli, Franco; Pession, Andrea; Fregoni, Vittorio; Montini, Elisa; Da Prada, Gian Antonio; Siena, Salvatore; Maccario, Rita.

In: International Journal of Cancer, Vol. 110, No. 1, 20.05.2004, p. 76-86.

Research output: Contribution to journalArticle

Montagna, Daniela ; Schiavo, Roberta ; Gibelli, Nadia ; Pedrazzoli, Paolo ; Tonelli, Roberto ; Pagani, Sara ; Assirelli, Elisa ; Locatelli, Franco ; Pession, Andrea ; Fregoni, Vittorio ; Montini, Elisa ; Da Prada, Gian Antonio ; Siena, Salvatore ; Maccario, Rita. / Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. In: International Journal of Cancer. 2004 ; Vol. 110, No. 1. pp. 76-86.
@article{49acbd8eae4542c384496b69d7fb6386,
title = "Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling",
abstract = "Successful ex-vivo priming and long-term maintenance of anti-tumor cytotoxic T-cell (CTL) lines are preliminary conditions for their use in approaches of adoptive immunotherapy for patients with cancer. We describe the results of a novel procedure for generating in vitro anti-tumor CTL using CD8-enriched peripheral blood mononuclear cells (PBMC) and dendritic cells (DC), pulsed with irradiated tumor cells (TC) as source of tumor antigen. Eight patients were enrolled in our study: 4 sarcoma, 2 renal cell carcinoma, 1 ovarian carcinoma and 1 breast carcinoma. Ten anti-tumor CTL-lines cytotoxic towards patient TC were generated. Five CTL-lines were obtained using both DC and PBMC from the patients (autologous setting). For 5 CTL-lines, DC derived from an HLA-identical sibling were employed (allogeneic setting): patients or siblings PBMC were used to generate CTL-lines in 2 and 3 cases, respectively,. After tumor-specific rounds of stimulation, followed by antigen-independent cycle of expansion, CTL-lines obtained in both autologous and allogeneic setting showed an expansion of the absolute number of cultured cells. In 6 of 10 CTL-lines, the majority of effector cells (>70{\%}) were CD3+/CD8+, while in the remaining 4, 40-70{\%} of effector cells were CD3+/CD4+. Both CD8+ and CD4+ T cells displayed anti-tumor cytotoxic activity. Spectratyping analysis of the TCR-Vβ subfamilies revealed a preferential expansion of oligoclonal populations in 18 of 24Vβ subfamily. Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy.",
keywords = "Adoptive immunotherapy, Dendritic cells, Graft- vs.-tumor, Solid tumors, Tumor-specific T-cell lines",
author = "Daniela Montagna and Roberta Schiavo and Nadia Gibelli and Paolo Pedrazzoli and Roberto Tonelli and Sara Pagani and Elisa Assirelli and Franco Locatelli and Andrea Pession and Vittorio Fregoni and Elisa Montini and {Da Prada}, {Gian Antonio} and Salvatore Siena and Rita Maccario",
year = "2004",
month = "5",
day = "20",
doi = "10.1002/ijc.20081",
language = "English",
volume = "110",
pages = "76--86",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling

AU - Montagna, Daniela

AU - Schiavo, Roberta

AU - Gibelli, Nadia

AU - Pedrazzoli, Paolo

AU - Tonelli, Roberto

AU - Pagani, Sara

AU - Assirelli, Elisa

AU - Locatelli, Franco

AU - Pession, Andrea

AU - Fregoni, Vittorio

AU - Montini, Elisa

AU - Da Prada, Gian Antonio

AU - Siena, Salvatore

AU - Maccario, Rita

PY - 2004/5/20

Y1 - 2004/5/20

N2 - Successful ex-vivo priming and long-term maintenance of anti-tumor cytotoxic T-cell (CTL) lines are preliminary conditions for their use in approaches of adoptive immunotherapy for patients with cancer. We describe the results of a novel procedure for generating in vitro anti-tumor CTL using CD8-enriched peripheral blood mononuclear cells (PBMC) and dendritic cells (DC), pulsed with irradiated tumor cells (TC) as source of tumor antigen. Eight patients were enrolled in our study: 4 sarcoma, 2 renal cell carcinoma, 1 ovarian carcinoma and 1 breast carcinoma. Ten anti-tumor CTL-lines cytotoxic towards patient TC were generated. Five CTL-lines were obtained using both DC and PBMC from the patients (autologous setting). For 5 CTL-lines, DC derived from an HLA-identical sibling were employed (allogeneic setting): patients or siblings PBMC were used to generate CTL-lines in 2 and 3 cases, respectively,. After tumor-specific rounds of stimulation, followed by antigen-independent cycle of expansion, CTL-lines obtained in both autologous and allogeneic setting showed an expansion of the absolute number of cultured cells. In 6 of 10 CTL-lines, the majority of effector cells (>70%) were CD3+/CD8+, while in the remaining 4, 40-70% of effector cells were CD3+/CD4+. Both CD8+ and CD4+ T cells displayed anti-tumor cytotoxic activity. Spectratyping analysis of the TCR-Vβ subfamilies revealed a preferential expansion of oligoclonal populations in 18 of 24Vβ subfamily. Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy.

AB - Successful ex-vivo priming and long-term maintenance of anti-tumor cytotoxic T-cell (CTL) lines are preliminary conditions for their use in approaches of adoptive immunotherapy for patients with cancer. We describe the results of a novel procedure for generating in vitro anti-tumor CTL using CD8-enriched peripheral blood mononuclear cells (PBMC) and dendritic cells (DC), pulsed with irradiated tumor cells (TC) as source of tumor antigen. Eight patients were enrolled in our study: 4 sarcoma, 2 renal cell carcinoma, 1 ovarian carcinoma and 1 breast carcinoma. Ten anti-tumor CTL-lines cytotoxic towards patient TC were generated. Five CTL-lines were obtained using both DC and PBMC from the patients (autologous setting). For 5 CTL-lines, DC derived from an HLA-identical sibling were employed (allogeneic setting): patients or siblings PBMC were used to generate CTL-lines in 2 and 3 cases, respectively,. After tumor-specific rounds of stimulation, followed by antigen-independent cycle of expansion, CTL-lines obtained in both autologous and allogeneic setting showed an expansion of the absolute number of cultured cells. In 6 of 10 CTL-lines, the majority of effector cells (>70%) were CD3+/CD8+, while in the remaining 4, 40-70% of effector cells were CD3+/CD4+. Both CD8+ and CD4+ T cells displayed anti-tumor cytotoxic activity. Spectratyping analysis of the TCR-Vβ subfamilies revealed a preferential expansion of oligoclonal populations in 18 of 24Vβ subfamily. Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy.

KW - Adoptive immunotherapy

KW - Dendritic cells

KW - Graft- vs.-tumor

KW - Solid tumors

KW - Tumor-specific T-cell lines

UR - http://www.scopus.com/inward/record.url?scp=11144358655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144358655&partnerID=8YFLogxK

U2 - 10.1002/ijc.20081

DO - 10.1002/ijc.20081

M3 - Article

C2 - 15054871

AN - SCOPUS:11144358655

VL - 110

SP - 76

EP - 86

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -